U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 183 results

TISOTUMAB VEDOTIN

MORE DETAILS

T41737F88A

Protein
Status:
US Approved Rx (2021)
First approved in 2021
Class:
PROTEIN

SACITUZUMAB GOVITECAN

MORE DETAILS

M9BYU8XDQ6

Protein
Status:
US Approved Rx (2020)
First approved in 2020
Class:
PROTEIN

TEPROTUMUMAB

MORE DETAILS

Y64GQ0KC0A

Protein
Status:
US Approved Rx (2020)
First approved in 2020
Class:
PROTEIN

TRASTUZUMAB DERUXTECAN

MORE DETAILS

5384HK7574

Protein
Status:
US Approved Rx (2019)
First approved in 2019
Class:
PROTEIN

ENFORTUMAB VEDOTIN

MORE DETAILS

DLE8519RWM

Protein
Status:
US Approved Rx (2019)
First approved in 2019
Class:
PROTEIN

POLATUZUMAB VEDOTIN

MORE DETAILS

KG6VO684Z6

Protein
Status:
US Approved Rx (2019)
First approved in 2019
Class:
PROTEIN

CEMIPLIMAB

MORE DETAILS

6QVL057INT

Protein
Status:
US Approved Rx (2018)
First approved in 2018
Class:
PROTEIN

GUSELKUMAB

MORE DETAILS

089658A12D

Protein
Status:
US Approved Rx (2017)
First approved in 2017
Class:
PROTEIN

INOTUZUMAB OZOGAMICIN

MORE DETAILS

P93RUU11P7

Protein
Status:
US Approved Rx (2017)
First approved in 2017
Class:
PROTEIN

OLARATUMAB

MORE DETAILS

TT6HN20MVF

Protein
Status:
US Approved Rx (2016)
First approved in 2016
Class:
PROTEIN
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966